Search Results for “Quiz 2024 EMC D-PDM-DY-23: Dell PowerProtect Data Manager Deploy 2023 Exam Updated Vce Download 🌋 Copy URL ➥ www.pdfvce.com 🡄 open and search for ⇛ D-PDM-DY-23 ⇚ to download for free 🥇Latest D-PDM-DY-23 Test Testking” – Page 7

Mast cells: makers and breakers of allergic inflammation

31.	Hakim-Rad, K., Metz, M., and Maurer, M.: Mast Cells: Makers and Breakers of allergic inflammation. Curr. Opin. Allergy Clin. Immunol. 2009: 9; 427-430. IF: 3.15

169.	Maurer, M.⁺, Khan, D. A., Komi, D. E. A., and Kaplan, A. P.: Biologics for the use in chronic spontaneous urticaria: when and which? J. Allergy Clin. Immunol. Pract. 2021: 9; 1067-1078. IF: 11.02

r.169

319	Siebenhaar, F.+, Sander, B., Ho, L. H. T., Ellrich, A., Maurer, M. and Weller, K.: Development and validation of the mastocytosis activity score. Allergy 2018: 73; 1489-1496. IF: 6.77

Breakthrough attacks in patients with hereditary angioedema receiving long-term prophylaxis are responsive to icatibant: findings from the icatibant outcome survey

279

Aberer, W.+, Maurer, M. Bouillet, L., Zanichelli, A., Caballero, T., Longhurst, H. J., Perrin, A., and Andresen, I.: Breakthrough attacks in patients with hereditary angioedema receiving long-term prophylaxis are responsive to icatibant: findings from the icatibant outcome survey. Allerg. Asthma Clin. Immunol. 2017: 13; 31. IF: 2.05

298	Staubach, P., Metz, M., Chapman-Rothe, N., Sieder, C., Bräutigam, M., Maurer, M. and Weller, K.+: Omalizumab rapidly improves angioedema-related quality of life in adult patients with chronic spontaneous urticaria: X-ACT study data. Allergy 2018: 73; 576-584. IF: 6.77

Use of biologicals in allergic and type-2 inflammatory diseases during the current COVID-19 pandemic: Position paper of Ärzteverband Deutscher Allergologen (AeDA), Deutsche Gesellschaft für Allergologie und Klinische Immunologie (DGAKI), Gesellschaft für Pädiatrische Allergologie und Umweltmedizin (GPA), Österreichische Gesellschaft für Allergologie und Immunologie (ÖGAI), Luxemburgische Gesellschaft für Allergologie und Immunologie (LGAI), Österreichische Gesellschaft für Pneumologie (ÖGP) in co-operation with the German, Austrian, and Swiss ARIA groups, and the European Academy of Allergy and Clinical Immunology (EAACI)

161.

Klimek, L., Pfaar, O., Worm, M., Eiwegger, T., Hagemann, J., Ollert, M., Untersmayr, E., Hoffmann-Sommergruber, K., Vultaggio, A., Agache, I., Bavbek, S., Bossios, A., Casper, I., Chan, S., Chatzipetrou, A., Vogelberg, C., Firinu, D., Kauppi, P., Kolios, A., Kothari, A., Matucci, A., Palomares, O., Szépfalusi, Z., Pohl, W., Hötzenecker, W., Rosenkranz, A. R., Bergmann, K. C., Bieber, T., Buhl, R., Buters, J., Darsow, U., Keil, T., Kleine-Tebbe, J., Lau, S., Maurer, M., Merk, H., Mösges, R., Saloga, J., Staubach, P., Jappe, U., Rabe, K. F., Rabe, U., Vogelmeier, C., Biedermann, T., Jung, K., Schlenter, W., Ring, J., Chaker, A., Wehrmann, W., Becker, S., Freudelsperger, L., Mülleneisen, N., Nemat, K., Czech, W., Wrede, H., Brehler, R., Fuchs, T., Tomazic, P. V., Aberer, W., Fink-Wagner, A. H., Horak, F., Wöhrl, S., Niederberger-Leppin, V., Pali-Schöll, I., Pohl, W., Roller-Wirnsberger, R., Spranger, O., Valenta, R., Akdis, M., Matricardi, P. M., Spertini, F., Khaltaev, N., Michel, J. P., Nicod, L., Schmid-Grendelmeier, P., Idzko, M., Hamelmann, E., Jakob, T., Werfel, T., Wagenmann, M., Taube, C., Jensen-Jarolim, E., Korn, S., Hentges, F., Schwarze, J., O Mahony, L., Knol, E. F., Del Giacco, S., Chivato Pérez, T., Bousquet, J., Bedbrook, A., Zuberbier, T., Akdis, C., Jutel, M.: Use of biologicals in allergic and type-2 inflammatory diseases during the current COVID-19 pandemic: Position paper of Ärzteverband Deutscher Allergologen (AeDA), Deutsche Gesellschaft für Allergologie und Klinische Immunologie (DGAKI), Gesellschaft für Pädiatrische Allergologie und Umweltmedizin (GPA), Österreichische Gesellschaft für Allergologie und Immunologie (ÖGAI), Luxemburgische Gesellschaft für Allergologie und Immunologie (LGAI), Österreichische Gesellschaft für Pneumologie (ÖGP) in co-operation with the German, Austrian, and Swiss ARIA groups, and the European Academy of Allergy and Clinical Immunology (EAACI). Allergol. Select. 2020: 4; 53-68. IF: N/A

r.161

Evaluating the minimally important difference of the urticaria activity score and other measures of disease activity in patients with chronic idiopathic urticaria

125

Mathias, S. D.+, Crosby, R. D., Zazzali, J. L., Maurer, M. and Saini, S. S.: Evaluating the minimally important difference of the urticaria activity score and other measures of disease activity in patients with chronic idiopathic urticaria. Ann. Allergy Asthma Immunol. 2012: 108; 20-24. IF: 3.44

419.	Bauer, A., Dickel, H., Jakob, T., Kleinheinz, A., Lippert, U., Metz, M., Schliemann, S., Schwichtenberg, U., Staubach, P., Valesky, E., Wagner, N., Wedi, B., and Maurer, M.⁺: Expert consensus on practical aspects in the treatment of chronic urticaria. Allergo J. Int. 2021. 30; 64-75. IF: N/A

o.419

Similar Efficacy with Omalizumab in Chronic Idiopathic/Spontaneous Urticaria Despite Different Background Therapy

211

Casale, T. B., Bernstein, J. A., Maurer, M. Saini, S. S., Trzaskoma, B., Chen, H., Grattan, C., Gimenèz-Arnau, A., Kaplan, A. P., and Rosén, K.+: Similar efficacy with Omalizumab in chronic idiopathic/spontaneous urticaria despite different background therapy. J. Allergy Clin. Immunol. Pract. 2015: 3; 743-750. IF: 5.42

251	Netchiporouk, E., Moreau, L., Rahme, E., Maurer, M. Lejtenyi, D., and Ben-Shoshan, M.+: Positive CD63 basophil activation tests are common in children with chronic spontaneous urticaria and linked to high disease activity. Int. Arch. Allergy Immunol. 2016: 171; 81-88. IF: 2.72

Results